|
Jun 30
|
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
|
|
Jun 30
|
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
|
|
Jun 25
|
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
|
Jun 19
|
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
|
|
Jun 18
|
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
|
|
Apr 17
|
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
|
|
Sep 30
|
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
|
|
Jul 22
|
Addex’s Partner Discontinues ADX71149 development in Epilepsy
|
|
May 8
|
Addex to Present at Bio€quity Europe 2024
|
|
Apr 29
|
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
|
|
Jan 9
|
Addex to Present at the Swiss Equities Baader Conference
|
|
Dec 20
|
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
|
|
Nov 29
|
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
|
|
Nov 28
|
Addex Convenes Extraordinary General Meeting
|
|
Nov 8
|
Addex Regains Nasdaq Listing Compliance
|
|
Aug 10
|
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
|